2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era

August 2, 2026

MiraScope Unknown

Overview

The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceuticals’ GalNAc-conjugated ASO, Olezarsen, had its use expanded by the FDA in June 2026 for severe hypertriglyceridemia. Fitusiran, an siRNA therapy from Sanofi and Alnylam, was approved in March 2025 for hemophilia A or B, offering infrequent subcutaneous dosing. Plozasiran, another siRNA from Arrowhead Pharmaceuticals, received EU marketing authorization in June 2026 for FCS.

In Depth

Key Findings

The year 2026 has been transformative for the field of RNA therapeutics, marked by several key approvals that firmly establish antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapies as robust treatment platforms. Notably, Ionis Pharmaceuticals’ GalNAc-conjugated ASO, Olezarsen, received expanded FDA approval for severe hypertriglyceridemia in June 2026. Fitusiran, an siRNA therapy from Sanofi and Alnylam, was approved in March 2025 for hemophilia A or B, offering the convenience of infrequent subcutaneous dosing. Furthermore, Arrowhead Pharmaceuticals’ Plozasiran secured EU marketing authorization in June 2026 for familial chylomicronemia syndrome (FCS).

Technical / Clinical Details

Olezarsen (Ionis Pharmaceuticals): This GalNAc-conjugated ASO is specifically delivered to the liver, where it targets and suppresses the mRNA of apolipoprotein C-III (ApoC-III). ApoC-III plays a crucial role in triglyceride metabolism, and its inhibition effectively lowers plasma triglyceride levels. The FDA’s expanded approval in June 2026 for patients with severe hypertriglyceridemia offers a new therapeutic option for those struggling with managing their condition with existing treatments.
Fitusiran (Sanofi and Alnylam): An siRNA therapy, fitusiran is designed to rebalance the coagulation cascade by suppressing the production of antithrombin (AT). AT is an endogenous protein that inhibits blood clotting, and reducing its levels improves coagulation ability in patients with hemophilia A or B. Approved in March 2025, its infrequent subcutaneous dosing regimen (once monthly) enhances patient convenience.
Plozasiran (Arrowhead Pharmaceuticals): Another siRNA therapy, plozasiran, is designed to inhibit the synthesis of angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is a critical regulator of lipid metabolism, and suppressing its expression effectively manages severe hypertriglyceridemia in FCS patients. Receiving EU marketing authorization in June 2026, it offers a new treatment for a rare disease with high unmet medical needs.

Background & Context

RNA therapeutics offer an innovative approach to treating diseases by intervening at the genetic level, addressing conditions that are often intractable with conventional drugs. ASOs and siRNAs function by degrading target mRNA or inhibiting its translation, thereby suppressing the production of specific proteins. The evolution of technologies like GalNAc conjugation and LNP (Lipid Nanoparticle) delivery has dramatically improved the specific and efficient delivery of nucleic acid drugs to the liver, significantly enhancing their clinical utility. These approvals signify that RNA therapeutics are gaining recognition as established treatment modalities across a wide range of disease areas, from rare conditions to common metabolic disorders.

Strategic Significance & Outlook

These approvals are expected to catalyze further research and development in RNA therapeutics, with an anticipated expansion of ASO and siRNA pipelines targeting various diseases and mechanisms. Key areas of focus will include developing specific delivery technologies to organs beyond the liver and designing drugs with less frequent dosing and sustained effects. RNA therapeutics are poised to become indispensable in shaping the future of medicine, offering new treatment options for personalized and refractory diseases. These successes further pave the way for treating diseases at the genetic level, globally.

Source: https://mira-scope.com/how-rna-therapeutics-are-changing-in-2026/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.